Salvectors

Salvectors is a clinical-stage biotechnology company focused on developing innovative gene therapies delivered directly to the salivary glands to treat chronic conditions. The company's lead program utilizes an adenoviral vector to deliver the human aquaporin-1 (hAQP1) gene to the parotid glands of patients suffering from severe xerostomia (dry mouth) caused by radiation therapy for head and neck cancer. By converting non-fluid secreting ductal cells into water-permeable cells, Salvectors aims to restore natural saliva production and significantly improve the quality of life for patients with salivary gland dysfunction. Beyond radiation-induced damage, the company is exploring applications for its localized delivery platform in autoimmune conditions such as Sjögren's syndrome.